Manipal Health Enterprises Ltd (MAINBOARD)

Incorporated in 2010 with origins dating back to 1991, Manipal Health Enterprises Limited is the largest pan-India multi-specialty hospital network by bed capacity. Part of the renowned Manipal Group, the company operates a network of 49 hospitals with over 12,600 licensed beds across 14 states, delivering advanced tertiary and quaternary care.

Business Verticals

• Core Specialty Care (CONGO-R): Providing specialized treatments across high-value healthcare fields like Cardiac sciences, Oncology, Neurosciences, Gastro sciences, Orthopaedics, and Renal sciences.

• Integrated Strategic Healthcare: Operating clinics, advanced diagnostic centers, and specialized organ transplant programs alongside a robust international medical tourism framework.

Track Record

• Financial Scale: Total operational income has shown exponential compounding, scaling up rapidly from ₹6,265.17 Cr in FY24 to ₹8,242.25 Cr for the fiscal year ended March 31, 2025.

• Profitability: Net profit (PAT) registered strong positive expansion, logging a robust ₹1,081.67 Cr alongside an EBITDA margin of 26.27% for FY25.

• Strategic Integration: Carries an established track record of expanding market presence through successful integrations of legacy hospital networks like Columbia Asia (2021), AMRI (2023), Medica Synergie (2024), and Sahyadri (2025).

Manipal Health Enterprises Ltd IPO GMP

As of July 17, 2026, the Grey Market Premium (GMP) is currently ₹0.

Note: Because the official price bands and subscription windows are awaiting immediate final disclosures, early grey market tracking indicators are currently flat.

Manipal Health Enterprises Ltd IPO Allotment Status

The allotment is tentatively scheduled to be finalized on July 30, 2026.

Check Manipal Health Allotment Status

To check your status online once the issue closes, visit the official exchange tracking portals or check the updates via the assigned registrar's allocation platform once active.

You can verify your status via:

• BSE and NSE official mainboard tracking portals

• Authorized Registrar's website (KFin Technologies Portal)

• Using your PAN number, Application ID, or DP ID/Client ID

Strengths

• Unrivaled Market Moat: Possesses the largest pan-India multi-specialty footprint by bed capacity, commanding leadership in major metros like Bengaluru, Kolkata, and Pune.

• Excellent Value Composition: Strong specialization in high-revenue quaternary and tertiary specialties ("CONGO-R") drives higher average revenue per occupied bed (AROB).

• Corporate De-leveraging Framework: A massive part of the fresh cash proceeds is structurally reserved to wipe out high subsidiary debt, which will heavily support future net margins.

Weaknesses

• Geographical Concentration Risk: Remains significantly exposed to localized regulatory changes and performance limits in Karnataka, which accounts for nearly half of its active operational revenues.

• High Operational Expenses: Hospital construction, clinical hardware procurement, and retaining specialized medical professionals involve heavy continuous asset outlays.

How the Company Will Use IPO Money

The fresh issue proceeds will be utilized for:

• Debt Repayment: Prepayment or repayment, in full or part, of specific outstanding borrowings availed by its material subsidiary, Manipal Hospitals Private Limited (₹5,378.00 Cr).

• Strategic Acquisitions: Financing the acquisition of the remaining minority stake in its step-down subsidiary, Sahyadri Hospitals Private Limited (₹574.00 Cr).

• General Corporate Purposes: Allocation toward day-to-day general administration, infrastructure optimization, and public issue administration overheads.

Lead Manager & Registrar

• Book Running Lead Managers: Kotak Mahindra Capital, Axis Capital, Goldman Sachs (India), Jefferies India, JP Morgan India, UBS Securities, and DBS Bank India.

• Registrar: KFin Technologies Limited